الفهرس 
Introduction & Aim of the Workيوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 118 |  |  |
| | | from | 118 | | |
المستخلص
ALL is a malignant transformation and proliferation of lymphoid progenitor cells in the BM, blood and extramedullary sites (Terwilliger& Abdul-Hay 2017).Leukemia and other tumors share the same biologic characteristic which is clonality. Molecular alterations are necessary for the development of malignancy and they have the ability to change the components of signaling pathway resulting in the emission of proliferative signals even when no more cells are required, inappropriately activating cell growth, DNA replication and cell division (Fujita et al ,2021).Different disease-related and patient-related factors might affect the prognosis of ALL cases (Roberts K. G. (2018).Downregulation of SOCS3 expression in leukaemia leads to continuous activation of JAK/STAT pathway, resulting in activation of anti-apoptotic genes as well as proliferation of cancer cells (Rozovski et al.,2016) This explain the lower CR rates in leukemic patients with low SOCS3 expression level.Alterations of SOCS3 expression are usually observed in cancers and might contribute to tumorigenesis, tumor progression, and relapse. The studies regarding clinical implications of SOCS3 expression in patients with acute ALL are few. We reported that those with lower expression had unfavorable cytogenetics, lower complete remission rates, greater primary refractory rates, and shorter OS. SOCS3 can serve as a new marker for prediction of clinical outcomes among ALL cases, and as a potential therapeutic target in patients with lower expression of this protein.